Exclusive By Damian Garde Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine
First Opinion By Darren Schulte The novel coronavirus is a serious threat. We need to prepare, not overreact
Biotech By Adam Feuerstein and Matthew Herper AstraZeneca to acquire Alexion for $39 billion, adding blockbuster immune medicines
Biotech By Kate Sheridan ‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation
First Opinion By Zach Nayer How much do doctors really make? Compare your salary to various specialties
First Opinion By Bob Kocher and Bryan Roberts Incentives and information drive health care innovation: lessons from Medicare Advantage
First Opinion By Til Schuermann and Helen Leis We stress tested banks in 2009. We need to do the same thing now for U.S. hospital systems
First Opinion By Cecile Riboud In biopharma mergers and acquisitions, managing regulatory compliance early protects return on investment
Biotech By Kate Sheridan Months of limbo at OpenBiome put fecal matter transplants on hold across the country
Biotech By Kate Sheridan Is Philadelphia’s biotech cluster faltering? Experts say no, even as funding dwindles
Biotech By Kate Sheridan How some biotechs are cramming multiple fundraising rounds into a single year
Health Tech By Rebecca Robbins and Erin Brodwin What we learned about the digital pharmacy business from Hims & Hers filing to go public
Pharmalot By Ed Silverman Not by the numbers: Former Aceto controller is charged with insider trading
Pharmalot By Ed Silverman Novartis sells bonds tied to expanding access to medicines in poor countries
First Opinion By Alexander Borsa, Joseph Bruch, and Sarah S. Richardson When private equity firms invest in women’s health clinics, who benefits?
Biotech By Kate Sheridan How much is a startup worth? For biotech companies, the answer is rarely public
Something Ventured By Kate Sheridan Oncorus and three other startups got venture funding a year ago. Did it help them do what they said it would?
Health Tech By Andy Rosen — Boston Globe Biofourmis raises $100 million for remote patient monitoring tools
Health Tech By Rebecca Robbins What we learned about the business of telemedicine from Amwell and GoodRx’s IPO filings
Health Tech By Rebecca Robbins STAT+ Conversations: 23andMe CEO says spit kit sales are picking up during the Covid-19 pandemic
Health Tech By Rebecca Robbins Otsuka approved to buy bankrupt smart-pill maker Proteus’ assets, overcoming opposition from Novartis
Special Report By Rebecca Robbins and Erin Brodwin How Teladoc won: The inside story of how well-timed bets propelled it ahead of the competition
Health Tech By Rebecca Robbins Johnson & Johnson invests in Thirty Madison, signaling the resilience of pharma’s interest in health tech
Biotech By Kate Sheridan 4 questions for neurology startups as venture investors pour millions into the field
The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein Listen: A health tech mega-deal, a Twitter vaccine debate, and media criticism from Operation Warp Speed